Acenxion Biosystems
Lawrence
About Acenxion Biosystems
Acenxion Biosystems is a privately funded medical device company that is developing rapid, gold standard, automated systems for phenotypic antimicrobial susceptibility testing (AST) and bacterial detection in blood cultures (Sepsis). Seamlessly fitting into current clinical workflows, Acenxion’s scalable fAST system(TM) reduces the time required for phenotypic testing to just 4-6 hours (versus 2 or more days), allowing clinicians rapid use of targeted precision treatment. Acenxion’s technology improves patient outcomes, reduces healthcare costs, and reduces the spread of antibiotic resistance, extending the useful life of antibiotics (Antibiotic Stewardship).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $5.3M
- Funding stage: Seed
- Last round: Seed (Aug 2024)
- Website: acenxionbiosystems.com
Industries & Categories
Biotechnology, Life Science, Medical, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/acenxion-biosystems-134119 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.